Przegalinski E, Witek K, Wydra K, Kotlinska JH, Filip M. 5-HT2c receptor stimulation in obesity treatment: orthosteric agonists vs. allosteric modulators. Nutrients. 2023;15(6):1449. https://doi.org/10.3390/nu15061449.

Food & Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market: potential risk of cancer outweighs the benefits. Accessed 1 Jul 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market.

DiNicolantonio JJ, Chatterjee S, O’Keefe JH, Meier P. Lorcaserin for the treatment of obesity? A closer look at its side effects. Open Heart. 2014;1(1)e000173. https://doi.org/10.1136/openhrt-2014-000173.

Garcia-Fernandez G, Krotter A, Gonzalez-Roz A, Garcia-Perez A, Secades-Villa R. Effectiveness of including weight management in smoking cessation treatments: a meta-analysis of behavioral interventions. Addict Behav. 2023;140:107606. https://doi.org/10.1016/j.addbeh.2023.107606.

Tian J, Venn A, Otahal P, Gall S. The association between quitting smoking and weight gain: a systemic review and meta-analysis of prospective cohort studies. Obes Rev. 2016;17(10):1014. https://doi.org/10.1111/obr.12448.

Article  PubMed  Google Scholar 

Okorare O, Evbayekha EO, Adabale OK, Daniel E, Ubokudum D, Olusiji SA, Antia AU. Smoking cessation and benefits to cardiovascular health: a review of literature. Cureus. 2023;15(3):e35966. https://doi.org/10.7759/cureus.35966.

Moyad MA. Preventing lethal prostate cancer with diet, supplements, and Rx: heart healthy continues to be prostate healthy and “first do no harm” part I. Curr Urol Rep. 2018;19:104. https://doi.org/10.1007/s11934-018-0846-4.

Article  PubMed  Google Scholar 

Wiggins T, Guidozzi N, Welbourn R, Ahmed AR, Markar SR. Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis. PLoS Med. 2020;17(7):e1003206. https://doi.org/10.1371/journal.pmed.1003206.

Syn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174772 participants. Lancet. 2021;397(10287):1830–41. https://doi.org/10.1016/S0140-6736(21)00591-2.

Article  PubMed  Google Scholar 

Wilson RB, Lathigara D, Kaushal D. Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk. Int J Mol Sci. 2023;24(7):6192. https://doi.org/10.3390/ijms24076192.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Urquhart S, Willis S. Long-acting GLP-1 receptor agonists: findings and implications of cardiovascular outcomes trials. JAAPA. 2020;33(8):19–30. https://doi.org/10.1097/01.JA.0000669452.63883.45.

Article  PubMed  Google Scholar 

Xu D, Nair A, Sigston C, Ho C, Li J, Yang D, et al. Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in nondiabetic populations. Cardiovasc Ther. 2022;2022:6820377. https://doi.org/10.1155/2022/6820377.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cifuentes L, Camilleri M, Acosta A. Gastric sensory and motor functions and energy intake in health and obesity-therapeutic implications. Nutrients. 2021;13(4):1158. https://doi.org/10.3390/nu13041158.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Panaro BL, Yusta B, Matthews D, Koehler JA, Song Y, Sandoval DA, Drucker DJ. Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion. Mol Metab. 2020;37:100990. https://doi.org/10.1016/j.molmet.2020.100990.

Holst JJ, Orskov C, Hartmann B, Deacon CF. Posttranslational processing of proglucagon and postsecretory fate of proglucagon products. Front Diabetes. 1997;13:24–48. https://doi.org/10.1159/000194728.

Article  CAS  Google Scholar 

• Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022;134(supp1):5–17. https://doi.org/10.1080/00325481.2022.2147326. One of the best cumulative objective reviews of the different phase 3 trials results utilizing semaglutide.

Article  PubMed  CAS  Google Scholar 

Smith EP, Polanco G, Yaqub A, Salehi M. Altered glucose metabolism after bariatric surgery: what’s GLP-1 got to do with it? Metabolism. 2018;83:159–66. https://doi.org/10.1016/j.metabol.2017.10.014.

Article  PubMed  CAS  Google Scholar 

Tacad DKM, Tovar AP, Richardson CE, Horn WF, Krishnan GP, Keim NL, Krishnan S. Satiety associated with calorie restriction and time-restricted feeding: peripheral hormones. Adv Nutr. 2022;13(3):792–820. https://doi.org/10.1093/advances/nmac014.

Article  PubMed  PubMed Central  Google Scholar 

Hu M, Kong Z, Shi Q, Nie J. Acute effect of high-intensity interval training versus moderate-intensity continuous training on appetite-regulating gut hormones in healthy adults: a systematic review and meta-analysis. Heliyon. 2023;9(2):e13129. https://doi.org/10.1016/j.heliyon.2023.e13129.

Deru LS, Chamberlain CJ, Lance GR, Gipson EZ, Bikman BT, Davidson LE, et al. The effects of exercise on appetite-regulating hormone concentrations over a 36-h fast in healthy young adults: a randomized cross-over study. Nutrients. 2023;15(8):1911. https://doi.org/10.3390/nu15081911.

Article  PubMed  PubMed Central  CAS  Google Scholar 

touchREV Endocrinol. Tirzepatide: a novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. 2022;18(1):10–9. https://doi.org/10.17925/EE.2022.18.1.10.

Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sorrig R, et al for the STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138–50. https://doi.org/10.1001/jama.2021.23619.

Wegovy (semaglutide injection 2.4 mg) Prescribing Information. Accessed 1 Jul 2023 at https://www.novo.pi.com/wegovy.pdf.

Ghusen W, De la Rose A, Sacoto D, Campos A, Feris F, Hurtado MD, Acosta A. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Network Open. 2022;5(9):e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982.

•• Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–64. https://doi.org/10.1111/dom.14725. One of the only studies to examine what happens when medication cessation occurs-two thirds of weight lost was regained within the first year of discontinuation.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth. 2023. https://doi.org/10.1007/s12630-023-02440-3.

Article  PubMed  Google Scholar 

Gulak MA, Murphy P. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. Can J Anaesth. 2023. https://doi.org/10.1007/s12630-023-02521-3.

Article  PubMed  Google Scholar 

Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB, et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023;87:111091. https://doi.org/10.1016/j.jclinane.2023.111091.

•• Joshi GP, Abdelmalak BB, Weigel WA, Soriano SG, Harbell MW, Kuo CI, et al. for the American Society of Anesthesiologists (ASA) Task Force on Preoperative Fasting. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. Accessed 1 Jul 2023 at https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative. One of the only current guidelines recommendations for surgical teams dealing with patients on these novel medications.

Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610–9. https://doi.org/10.1111/dom.13120.

Article  PubMed  CAS  Google Scholar 

•• Gorgojo-Martinez JJ, Mazquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, de Torres-Sanchez A, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12:145. https://doi.org/10.3390/jcm12010145. One of the only comprehensive guides published to date on how to prevent and manage some of the most common side effects of these weight loss medications.

Article  CAS  Google Scholar 

Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105. https://doi.org/10.1111/dom.14551.

Lingvay I, Hansen T, Macura S, Marre M, Nauck MA, de la Rosa R, et al. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Res Care. 2020;8(2):e001706. https://doi.org/10.1136/bmjdrc-2020-001706.

Zhou F, Jiang L, Jiamei G, Fan Y, Pan Q, Tianlian L, et al. Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes. Ther Adv Chronic Dis. 2023;14:20406223231161516. https://doi.org/10.1177/20406223231161516.

Article  PubMed  PubMed Central  Google Scholar 

FDA approves once-weekly Wegovy® injection for the treatment of obesity in teens aged 12 and older. Accessed 1 Jul 2024 at https://www.novonordisk-us.com/media/news-archive/news-details.html?id=151389.

Weghuber D, Barrett T, Barrientos-Perez M, Gies I, Hesse D, Jeppesen OK, et al. for the STEP TEENS Investigators. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022. 387(24):2245–57. https://doi.org/10.1056/NEJMoa2208601.

FDA approves new drug treatment for chronic weight management, first since 2014. Accessed 1 Jul 2023 at https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014.

• Kanerva N, Larrson I, Peltonen M, Lindroos A-K, Carlsson LM. Changes in total energy intake and macronutrient composition after bariatric surgery predict long-term weight outcome: findings from the Swedish Obese Subjects Study. Am J Clin Nutr. 2017;106(1):136–45. https://doi.org/10.3945/ajcn.116.149112. The main manuscript and supplementary index provide a rare glimpse into the quantity and quality of caloric intakes, which impact short and long-term weight loss after bariatric surgery.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Giusti V, Theytaz F, Di Vetta V, Clarisse M, Sutter M, Tappy L. Energy and macronutrient intake after gastric bypass for morbid obesity: a 3-y observational study focused on protein consumption. Am J Clin Nutr. 2016;103(1):18–24. https://doi.org/10.3945/ajcn.115.111732.

Article  PubMed  CAS  Google Scholar 

Reichmann MTF, Duarte A, Ivano F, Campos ACL. Evolution of the basal metabolic rate after Roux-en-Y gastric bypass: a systematic review and meta-analysis. Updates Surg. 2023. https://doi.org/10.1007/s13304-023-01523-6.

Article  PubMed  Google Scholar 

Moehlecke M, Blume CA, Rheinheimer J, Trindade MRM, Crispim D, Leitao CB. Early reduction in energy expenditure and successful weight loss after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2017;13(2):204–9. https://doi.org/10.1016/j.soard.2016.08.027.

Article  PubMed  Google Scholar 

Monnier L, Schlienger J-L, Colette C, Bonnet F. The obesity treatment dilemma: why dieting is both the answer and the problem? A mechanistic overview. Diabetes Metab. 2021;47(3):101192. https://doi.org/10.1016/j.diabet.2020.002.

Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):1–7. https://doi.org/10.2337/dc22-1710.

Article  CAS  Google Scholar 

Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabes Obes Metab. 2017;19(9):1242–51. https://doi.org/10.1111/dom.12932.

Article  CAS  Google Scholar 

Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–62. https://doi.org/10.1111/dom.14280.

Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(2):581–8. https://doi.org/10.1111/dom.14255.

Article  PubMed  CAS  Google Scholar 

Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes Metab Syndr Obes. 2023;16:575–95. https://doi.org/10.2147/DMSO.S387116.

Article